Mereo BioPharma said it had signed a license agreement with Oncologie for the development and sale of a treatment for ovarian cancer. Oncologie would receive an exclusive worldwide license for the treatment, called navicixizumab. In return, Mereo would get an upfront payment of $4m with an additional payment of $2m conditional on a chemistry, manufacturing and controls milestone. Mereo said it would also be eligible to receive up to $300m in future clinical, regulatory and commercial milestones, royalties and a negotiated percentage of sublicensing revenues. 'We believe Oncologie is expertly positioned to further advance navicixizumab through clinical development and towards potential commercialization,' said chief executive Denise Scots-Knight. 'While we believe navicixizumab is an exciting oncology asset, we continue to focus our primary efforts on the development of our innovative rare disease portfolio.' At 1:18pm: (LON:MPH) Mereo Biopharma Group Ltd share price was +0.5p at 33.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.